News

Japan's Pharmaceuticals and Medical Devices Agency publishes assessment report of Tresiba® (19 October 2012)

Read the full announcement in PDF format

Novo Nordisk today announced that Japan's Pharmaceuticals and Medical Devices Agency (PMDA) has published their assessment report of Tresiba® (insulin degludec). The report forms the basis of the approval of the product announced on 28 September 2012.

Further information:


Media:
Investors:
Mike Rulis Kasper Roseeuw Poulsen
Tel: (+45) 3079 3573 Tel: (+45) 4442 4303
mike@novonordisk.com krop@novonordisk.com
Frank Daniel Mersebach
Tel: (+45) 4442 0604
fdni@novonordisk.com
Lars Borup Jacobsen
Tel: (+45) 3075 3479
lbpj@novonordisk.com
In North America:
Ambre Morley Jannick Lindegaard
Tel: (+1) 609 216 5240 Tel: (+1) 609 786 4575
abmo@novonordisk.com jlis@novonordisk.com

Company Announcement No 65 / 2012

 

 

 

  •  
Search for Danish versions and earlier news releases:

Language
Year
Month
Type
Search for:

Search
  •  
  •  

Sign up for the latest news from Novo Nordisk

SMS/e-mail

Twitter

Facebook

RSS feeds

 
  •  
  •  
Pipeline
  •  
  •  
Click here to go to the download centre to download presenations, reports or magazines
  •